Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets on time scales not previously achievable in nucleic acid drug development.
Creyon Bio Appoints Industry Leader, Serge Messerlian as CEO, Leveraging Decades of Company Building and Strategic Collaborations
Creyon Bio, Inc. ("Creyon") today announced the appointment of industry leader, Serge Messerlian as Chief Executive Officer, effective immediately. Mr. Messerlian brings Creyon Bio a track record in both multinational pharmaceutical and biotechnology leadership as well as company building and strategic collaborations across a range of disease areas including hematology, oncology, immunology, and rare diseases as well as novel technology platforms.
